What’s Up with U.S. Merger Remedies? A Podcast Episode Featuring Jeny Maier
February 26, 2024, 3:14 PM
By: Axinn Insights
The US antitrust agencies’ approach to merger remedies has undergone a significant change under the Biden administration. Remedies are increasingly disfavored.
Axinn's Managing Partner Jeny Maier joins Dan Ducore, former Assistant Director of the Federal Trade Commission’s Bureau of Competition Compliance Division, and co-host Barry Nigro on Our Curious Amalgam to discuss the growing skepticism towards merger remedies by the US antitrust authorities.
Listen to this episode to learn more about whether merger remedies remain a viable option in the US and, if so, how parties should approach them given the government’s current hostility toward remedies.
To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
ABA 2026 Antitrust International Cartel Workshop
Speaking Engagement
Antitrust
Annual Checkup from the ABA Antitrust in Healthcare Conference
Axinn Viewpoints
Antitrust
The Skinny Line Between Possible and Plausible
Axinn Viewpoints
Intellectual Property
The Empty Chair in Antitrust Conspiracy Cases
Webinar
Antitrust
2026 Concurrences International Mergers Conference
Speaking Engagement
Antitrust
Axinn Expands Chambers USA Rankings Across Practices and Individuals in 2026 Guide
News
Antitrust
USC Gould/Analysis Group Global Competition Law Thought Leadership Conference
Speaking Engagement
Antitrust
17th ACI Summit on Biosimilars & Innovator Biologics
Speaking Engagement
Intellectual Property
GCR Live: Europe 2026
Speaking Engagement
Antitrust
Fixing “Litigate the Fix”: Insights from the FTC’s Workshop
Axinn Viewpoints
Antitrust